Natus Medical Inc. (BABY) Lowered to “Hold” at Zacks Investment Research
According to Zacks, “Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories. “
Separately, Raymond James Financial Inc. raised Natus Medical from a market perform rating to an outperform rating and set a $46.00 price objective on the stock in a research note on Tuesday, September 13th.
Natus Medical (NASDAQ:BABY) opened at 39.89 on Wednesday. Natus Medical has a one year low of $29.54 and a one year high of $51.05. The firm’s 50-day moving average price is $40.37 and its 200 day moving average price is $36.81. The firm has a market capitalization of $1.29 billion, a P/E ratio of 34.39 and a beta of 0.85.
Natus Medical (NASDAQ:BABY) last released its earnings results on Wednesday, July 20th. The company reported $0.39 EPS for the quarter, beating the Zacks’ consensus estimate of $0.36 by $0.03. The business had revenue of $96 million for the quarter, compared to analysts’ expectations of $92.71 million. Natus Medical had a return on equity of 13.82% and a net margin of 10.20%. The firm’s revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.34 earnings per share. On average, equities analysts anticipate that Natus Medical will post $1.58 earnings per share for the current fiscal year.
In related news, insider James B. Hawkins acquired 10,000 shares of the stock in a transaction on Wednesday, September 28th. The stock was acquired at an average cost of $38.48 per share, for a total transaction of $384,800.00. Following the completion of the acquisition, the insider now directly owns 459,725 shares of the company’s stock, valued at approximately $17,690,218. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.80% of the stock is currently owned by company insiders.
Hedge funds have recently modified their holdings of the company. Norges Bank bought a new stake in shares of Natus Medical during the fourth quarter valued at approximately $15,163,000. Aperio Group LLC raised its stake in shares of Natus Medical by 37.3% in the first quarter. Aperio Group LLC now owns 8,823 shares of the company’s stock valued at $339,000 after buying an additional 2,398 shares during the period. Pacad Investment Ltd. bought a new stake in shares of Natus Medical during the first quarter valued at approximately $284,000. TIAA CREF Investment Management LLC raised its stake in shares of Natus Medical by 11.0% in the first quarter. TIAA CREF Investment Management LLC now owns 199,288 shares of the company’s stock valued at $7,659,000 after buying an additional 19,809 shares during the period. Finally, Mckinley Capital Management LLC Delaware raised its stake in shares of Natus Medical by 11.8% in the first quarter. Mckinley Capital Management LLC Delaware now owns 190,309 shares of the company’s stock valued at $7,314,000 after buying an additional 20,087 shares during the period. Institutional investors and hedge funds own 87.92% of the company’s stock.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Stock Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related stocks with our FREE daily email newsletter.